Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine

European Respiratory Journal

Volumn 48, Issue 5, 2016, Pages 1526-1527

  Wallis, Robert S ^a  

^a AURUM INSTITUTE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; CLOFAZIMINE; DELAMANID; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; ERYTHEMA NODOSUM LEPROSUM; HEART VENTRICLE TACHYCARDIA; HUMAN; LETTER; OPEN STUDY; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; QTC INTERVAL; QTCF INTERVAL; RECURRENT DISEASE; STEADY STATE; TORSADE DES POINTES; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS;

ANTITUBERCULAR AGENTS; CLOFAZIMINE; DIARYLQUINOLINES; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; NITROIMIDAZOLES; OXAZOLES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84994205156     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01207-2016     Document Type: Letter

References (11)

1. Tadolini M, Lingtsang RD, Tiberi S, et al. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline. Eur Respir J 2016; 48: 935-938.
2. Fridericia LS. The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. 1920. Ann Noninvasive Electrocardiol 2003; 8: 343-351.
3. Deltyba summary of product characteristics. Report number WC500166232. European Medicines Agency 2015. www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002552/WC500166232.pdf Date last accessed: July 12, 2016.
4. Dannemann B, Bakare N, De Marez T, et al. QTcF prolongation in a phase II trial of TMC207 plus background regimen as treatment for MDR-TB: effect of co-administration of clofazimine. ICAAC 2012; 52: A1259.
5. Everitt D. Clofazimine in clinical trials for tuberculosis. Resurrecting clofazimine. www.resisttb.org/wp-content/uploads/2013/08/Global-Alliance-Clinical-Work-with-Clofazimine.pdf Date last accessed: July 12, 2016.
6. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 2006; 440: 463-469.
7. Hedley PL, Jørgensen P, Schlamowitz S, et al. The genetic basis of long QT and short QT syndromes: a mutation update. Hum Mutat 2009; 30: 1486-1511.
8. S7B Nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. Report number UCM074963. US FDA 2005. www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm074963.pdf Date last accessed: July 12, 2016.
9. Vicente J, Johannesen L, Mason JW, et al. Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine, and verapamil. J Am Heart Assoc 2015; 4: pii: e001615.
10. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med 2015; 191: 943-953.
11. Choudhri SH, Harris L, Butany JW, et al. Clofazimine induced cardiotoxicity -a case report. Lepr Rev 1995; 66: 63-68.